The invention is directed to compositions comprising at least one nanoparticulate H 1-histamine receptor antagonist, such as ebastine or a salt or derivative thereof, having improved dissolution rate providing a faster onset of drug availability. The nanoparticulate H1-histamine receptor antagonist particles, such as ebastine, have an effective average particle size of less than about 2000 nm and are useful in the treatment of seasonal and perennial allergic rhinitis and related diseases.
申请公布号
WO2006135689(A3)
申请公布日期
2007.06.14
申请号
WO2006US22330
申请日期
2006.06.08
申请人
ELAN PHARMA INTERNATIONAL, LIMITED;LIVERSIDGE, GARY, G.;JENKINS, SCOTT